Glp-1 has been reported to have clinical benefits in the treatment of moderate PD [34–36], but no significant difference in serum Glp-1 was observed among the groups in our study, hence excluding the possibility of Glp-1 related effect. This evidence concerns the gene GCG and Parkinson disease.